Health Update: Community Transmission of Clade I Mpox in the United States
Disease Prevention and ControlSituational Update
Clade I mpox is now circulating in California and throughout the United States. Previously, all clade I mpox cases reported in San Francisco (SF) were associated with international travel, but an increasing proportion of clade I mpox in SF has been among patients with no recent international travel or known links to people who recently traveled, suggesting local acquisition of the infection.
The mpox outbreak in the United States that began in 2022 was due to clade II mpox and led to a total of 1108 clade II mpox cases in SF as of November 12, 2026. In contrast, an outbreak of clade I mpox in Central and Eastern Africa has been ongoing since 2023, with sporadic travel-associated cases reported in non-endemic countries; starting in 2025, there were increasing reports of locally acquired clade I mpox in Europe. Since August 2026, there have been increased reports of locally acquired clade I mpox in the United States, including California. As of November 12, there have been 16 clade I mpox cases in SF.
The signs and symptoms of mpox are similar across clade I and clade II mpox, though officials are still learning if and how severity differs between clades. Most people with clade I mpox in the U.S. have had relatively mild illness and there have been no associated deaths. Testing, clinical management, prevention and public health reporting are the same regardless of clade.
Recommendations for SF Clinicians
Prevention
- Recommend JYNNEOS vaccination to people who would benefit.
- Include assessment of mpox risk and vaccination status at all visits for men, trans, or nonbinary people who have sex with men, trans, or nonbinary people.
- The two doses are administered 28 days apart. If a person received 1 dose >28 days ago, the second dose can be administered immediately.
- The vaccine is safe for people who are immunocompromised or taking immune suppressing medications.
- Vaccination is not recommended in persons who have previously been diagnosed with mpox as infection confers immune protection.
- Booster doses are not recommended.
- For information about where to get the vaccine, patients can check our website for more information.
- Counsel patients that vaccination with JYNNEOS significantly reduces the risk of mpox infection and severe disease but is not 100% effective at preventing all disease. Condom use and reducing the number of sex partners are additional strategies to reduce risk.
Diagnosis, Testing, and Infection Control
- Recognize that both clade I mpox and clade II mpox may present with flu-like symptoms, including fevers, chills, lymphadenopathy or malaise, for several days before or simultaneously with development of mpox lesions.
- Recognize and test suspected lesions. Follow specimen collection guidelines and your laboratory’s submission criteria to submit 2 swabs, 1 each from separate lesions.
- Presume that patients with NVO+/clade II negative results have clade I mpox.
- NVO+/clade II negative specimens are automatically routed to CDPH for clade determination for surveillance purposes therefore providers do not need to request expedited clade I mpox testing.
- Follow infection prevention and control recommendations for all patients with mpox symptoms.
Treatment
- Provide supportive care and symptomatic treatment to patients diagnosed with clade I or clade II mpox.
- There is no FDA-approved treatment for clade I or clade II mpox.
- TPOXX monotherapy was not found to be effective for patients with mild to moderate mpox.
- Consider use of TPOXX in combination with brincidofovir for patients with severe immunocompromise or patients at risk of severe disease.
- To request TPOXX and brincidofovir for a patient who meets CDC eligibility criteria, contact SFDPH at the phone numbers provided below.
Reporting
- Notify SFDPH within 24 hours of clade I or II mpox if there is an ICU admission, mpox-related death, or diagnosis of mpox in a child, person assigned female at birth, or cis man with cis female or trans male sex partner(s).
- Report all other clade I and II mpox cases by submitting a CMR by email (DPH-STIReactorDesk@sfdph.org) or fax: (628) 217-6603.
Need assistance after-hours, on weekends or on holidays? Call 628-217-6100 and follow instructions to page the on-call physician.
Resources
- Likely Community Transmission of Clade I Mpox Within California and the US: Updated Guidance | CDPH
- Mpox case counts | SF.gov
- Clade I Monkeypox Outbreaks | Monkeypox | CDC
- Clinical Overview of Clade I and Clade II Monkeypox | Monkeypox | CDC
- Clinical Signs and Symptoms of Monkeypox | Monkeypox | CDC
- Mpox Clinical Recognition and Testing Quicksheet | CDPH
- Get mpox vaccines, testing, and treatment | SF.gov
- Mpox resources for SF providers | SF.gov
- Vaccine for Monkeypox Prevention in the United States | Monkeypox | CDC
- Diagnostic Testing for Monkeypox | Monkeypox | CDC
- Collecting and Handling Specimens for Monkeypox PCR Testing | Monkeypox | CDC
- Infection Prevention and Control in Healthcare Settings | Monkeypox | CDC
- Pain Management and Supportive Care | Monkeypox | CDC
- Tecovirimat for the Treatment of Mpox | New England Journal of Medicine
- Tecovirimat-IND-Protocol-CDC-IRB | CDC
More information about mpox can be found here:
- Monkeypox in the United States and Around the World: Current Situation | Monkeypox | CDC
- Mpox - What You Need to Know | CDPH
- Free CME: Mpox - STD Lessons | National STD Curriculum
To view or sign up for SFDPH Health Alerts, Advisories, and Updates visit: sf.gov/healthalerts